SELECT: Obesity & Heart Health

Semaglutide, marketed as Ozempic or Wegovy and administered at a weekly dosage of 2.4 mg, has demonstrated a noteworthy reduction in cardiovascular events by 20% among non-diabetic individuals with obesity. Most participants had a diagnosis of prediabetes and a history of either myocardial infarction (MI) or stroke at the beginning of the study.